Abbott, AbbVie Must Produce Adverse Event Reports For AndroGel Testosterone
Mealey's (June 24, 2016, 11:42 AM EDT) -- CHICAGO — The Illinois federal judge overseeing the testosterone multidistrict litigation on June 22 granted a plaintiffs’ motion compelling defendants Abbott Laboratories and AbbVie Inc. to produce full drug safety and investigation files for 269 adverse events reported to the Food and Drug Administration concerning AndroGel (In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL Docket No. 2545, No. 14-1748, N.D. Ill., Eastern Div.).